I am a
Home I AM A Search Login

Papers of the Week


Papers: 5 Oct 2019 - 11 Oct 2019


Human Studies, Pharmacology/Drug Development

PAIN TYPE:
Migraine/Headache


2020 Mar


Eur J Neurol


27


3

Positive Response to Galcanezumab Following Treatment Failure to OnabotulinumtoxinA in Patients With Migraine: Post hoc Analyses of 3 Randomized Double-Blind Studies.

Abstract

Humanized monoclonal antibody galcanezumab, which binds to calcitonin gene-related peptide, has shown efficacy for episodic and chronic migraine prevention. These analyses evaluated galcanezumab response for migraine headache prevention in patients who previously failed onabotulinumtoxinA ("nonresponse" or "inadequate response" or safety reasons).